A B S T R A C T Hypertyraminemia is common in hepatic cirrhosis and correlates in severity with encephalopathy. The mechanism of cirrhotic hypertyraminemia has not been established. The alternative possibilities are increased production from tyrosine and impaired degradation by monoamine oxidase. This investigation determined the pharmacokinetics of tyramine after an intravenous bolus injection of [3H]-tyramine uCi,12 Ci/mmol sp act) in 13 cirrhotics and 9 controls. In normals, [3H]tyramine levels initially declined rapidly (a-phase) followed by a slower decline (,8-phase) with an average t1/2 of20.8 min. Average normal metabolic clearance rate and production rate were 13.2 liters/min and 15.4 ,ug/min, respectively.In cirrhotic patients, the plasma disappearance curve for [3H]tyramine was qualitatively similar to that of the control subjects with no apparent difference in _3-t1/2 (17.2 min). The hypertyraminemia of cirrhosis resulted primarily from overproduction of tyramine, as the production rate (32.0 ,Lg/min) in these patients was significantly greater (P < 0.05) than in controls, whereas the metabolic clearance rate remained normal (average 12.2 liters/min). A difference in ratio of tyramine metabolic products was noted as well. Cirrhotics had a high ratio of plasma 4-hydroxyphenylethanol:4-hydroxyphenylacetic acid (60:40 vs. 30:70) fects on circulatory and neurologic functions, which are often disturbed in cirrhotics (1-5). An understanding of the mechanism of the hypertyraminemia of cirrhotic patients is therefore desirable. The accumulation of tyramine in plasma could result from increased production, decreased degradation, or a combination of both effects.Tyramine is produced by decarboxylation of tyrosine (Fig. 1). Plasma tyrosine is elevated in cirrhotics (6-8), and tyrosine tolerance is impaired (9), therefore more tyrosine is available for tyramine formation than in normals. Tyramine is also produced in the gastrointestinal tract by bacterial decarboxylation of tyrosine and may enter the systemic circulation via portasystemic shunts.Tyramine is degraded by monoamine oxidase, of which the major proportion is located in the liver. Accordingly, tyramine degradation could be delayed in cirrhosis because ofhepatocellular disease, diminished hepatic blood flow, or both.In this study, we have measured the production rate and metabolic clearance rate of plasma tyramine in normals and in cirrhotics with a pharmacokinetic technique. The kinetics of tyramine were correlated with the clinical status of the liver patients, the fasting plasma tyrosine, and the tyrosine tolerance. A hypothesis relating hypertyraminemia and hypertyrosinemia was developed from the results.
METHODS
Materials[3H]Tyramine (11.6 Ci/mmol sp act) was obtained from New England Nuclear (Boston, Mass.). Radiochemical purity, evaluated by analytic thin-layer chromatography with three different solvent systems (10)
SubjectsThe control group consisted of 11 healthy adult volunteers, 9 males and 2 females, with no history of hepatobiliary d...